|
EP4137128A1
(en)
|
2008-09-02 |
2023-02-22 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
|
|
MX2011004077A
(es)
|
2008-10-17 |
2011-08-17 |
Metabolex Inc |
Metodos para reducir particulas de ldl densas, pequeñas.
|
|
US20120093922A1
(en)
|
2009-04-29 |
2012-04-19 |
Amarin Corporation Plc |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
US20120100208A1
(en)
|
2009-04-29 |
2012-04-26 |
Amarin Pharma, Inc. |
Stable pharmaceutical composition and methods of using same
|
|
SG177254A1
(en)
|
2009-06-15 |
2012-02-28 |
Ian Osterloh |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US20110071176A1
(en)
|
2009-09-23 |
2011-03-24 |
Amarin Pharma, Inc. |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
WO2012074930A2
(en)
|
2010-11-29 |
2012-06-07 |
Amarin Pharma, Inc. |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
|
ES2891473T3
(es)
|
2012-01-06 |
2022-01-28 |
Amarin Pharmaceuticals Ie Ltd |
Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
|
|
PT4342546T
(pt)
|
2012-06-29 |
2025-09-01 |
Amarin Pharmaceuticals Ie Ltd |
Éster etílico do ácido eicosapentanoico para utilização na redução do risco de acidente vascular cerebral não-fatal num indivíduo em terapia com estatina
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
US9486428B2
(en)
|
2014-03-20 |
2016-11-08 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
HRP20192299T1
(hr)
|
2014-04-11 |
2020-03-06 |
Cymabay Therapeutics, Inc. |
Liječenje nafld i nash
|
|
ES2860423T3
(es)
|
2014-05-28 |
2021-10-05 |
Childrens Hospital Med Ct |
Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
CA2963704A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
CA2980296A1
(en)
*
|
2015-03-26 |
2016-09-29 |
T3D Therapeutics, Inc. |
Methods of treating liver disease using indane acetic acid derivatives
|
|
KR20240033300A
(ko)
|
2015-04-28 |
2024-03-12 |
바스프 에이에스 |
비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
CN116790476A
(zh)
|
2016-05-05 |
2023-09-22 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
GB201614455D0
(en)
*
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
EP3534907A4
(en)
|
2016-11-04 |
2020-06-24 |
Children's Hospital Medical Center |
COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
CA3045145A1
(en)
|
2016-12-05 |
2018-06-14 |
Children's Hospital Medical Center |
Colonic organoids and methods of making and using same
|
|
US12281334B2
(en)
|
2017-04-14 |
2025-04-22 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
WO2018204775A1
(en)
|
2017-05-05 |
2018-11-08 |
Hepanova, Inc. |
Amino-aryl-benzamide compounds and methods of use thereof
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
JP2020533339A
(ja)
|
2017-09-13 |
2020-11-19 |
ノバルティス アーゲー |
Ｆｘｒアゴニストを含む組合せ
|
|
WO2019074793A1
(en)
|
2017-10-10 |
2019-04-18 |
Children's Hospital Medical Center |
OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
|
|
EP3701953A4
(en)
*
|
2017-10-27 |
2021-06-16 |
Samyang Corporation |
COMPOSITION FOR THE PREVENTION OR RELIEF OF NON-ALCOHOLIC FAT LIVER DISEASE
|
|
CA3084728A1
(en)
|
2017-12-06 |
2019-06-13 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|
|
EP3727394A4
(en)
|
2017-12-21 |
2021-09-08 |
Children's Hospital Medical Center |
DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
CA3106634A1
(en)
|
2018-07-26 |
2020-01-30 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
US12428622B2
(en)
|
2018-09-12 |
2025-09-30 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
DK4056176T3
(da)
|
2018-09-24 |
2024-05-06 |
Amarin Pharmaceuticals Ie Ltd |
Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ
|
|
BR112021009038A2
(pt)
*
|
2018-11-16 |
2021-08-10 |
Cymabay Therapeutics, Inc. |
tratamento combinado de nafld e nash
|
|
EP3880187A1
(en)
|
2018-11-16 |
2021-09-22 |
CymaBay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
AU2020283048A1
(en)
|
2019-05-31 |
2021-12-23 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
US12497597B2
(en)
|
2019-05-31 |
2025-12-16 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
AU2020336272A1
(en)
|
2019-08-23 |
2022-04-14 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
EP4028008A4
(en)
|
2019-09-12 |
2023-09-13 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
US12427134B2
(en)
|
2019-11-12 |
2025-09-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
|
|
US20210145774A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Treatment of alcoholic liver disease
|
|
US20210145775A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Treatment of intestinal barrier dysfunction and associated diseases
|
|
KR20230024277A
(ko)
*
|
2020-05-13 |
2023-02-20 |
테른스 파마슈티칼스, 인크. |
간 장애의 조합 치료
|
|
WO2022225896A1
(en)
|
2021-04-21 |
2022-10-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
WO2022238450A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|